Serum phosphorylated tau 217 in GBA1 variant carriers with and without Parkinson disease
Open Access
- 22 January 2026
- journal article
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (2) , 258-265
Abstract
It is unclear whether Alzheimer disease pathology drives cognitive decline in Parkinson disease (PD) patients carrying GBA1 variants. We evaluated levels of serum phosphorylated tau 217 (p-tau217) in samples from 29 GBA1 -PD, 32 idiopathic PD, 20 non-manifesting GBA1 variant carriers ( GBA1 -NMC) and 31 healthy controls. No differences were detected between PD groups. GBA1 -NMCs showed higher levels than healthy controls, which correlated to worse cognition and subthreshold parkinsonism. Serum p-tau217 is not a marker of cognitive decline in GBA1 -PD. Whether p-tau217 levels in GBA1 -NMCs can predict conversion to PD or are a marker of cognitive decline, irrespective of PD, remains unknown.Keywords
This publication has 34 references indexed in Scilit:
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease PathologyJAMA Neurology, 2024
- Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body DiseaseMovement Disorders, 2020
- Penetrance of Glucocerebrosidase (GBA) Mutations in Parkinson's Disease: A Kin Cohort StudyMovement Disorders, 2020
- Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative DisordersJAMA, 2020
- Update of the MDS research criteria for prodromal Parkinson's diseaseMovement Disorders, 2019
- Cognitive impairment in Glucocerebrosidase (GBA)‐associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profilesMovement Disorders, 2017
- No evidence for substrate accumulation in Parkinson brains with GBA mutationsMovement Disorders, 2015
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing resultsMovement Disorders, 2008
- The REM sleep behavior disorder screening questionnaire—A new diagnostic instrumentMovement Disorders, 2007
- Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA‐AUTMovement Disorders, 2004